New Drug Development Services
iHuPDX models
- Categories:Oncology in vivo
- Time of issue:2023-09-07 16:02:13
- Views:0
Introduction
Under the technological guidance of InnovateBio, we proudly present the innovative InnovateBio PDX In Vivo Drug Efficacy Model. Leveraging primary cell engraftment techniques, we've crafted an unparalleled efficacy model with unique features that ensure stability and growth rate consistency. As early uniform growth is achieved, experimental efficiency is maximized. Join us as we unveil the enigmatic facets of this model that is redefining the realm of efficacy evaluation.
Platform Highlights
● Homogeneous Modeling of Batch Samples
Our model is formulated through the suspension of cells, guaranteeing homogeneity among samples from the same batch. This implies that samples within the same batch exhibit remarkable consistency in growth rate and biological attributes, establishing a firm foundation for model stability.
● Stability and Consistency Across Generations
Homogenizing samples from the same batch ensures stability across generations. This sustains uniform growth and efficacy characteristics over prolonged studies, ensuring the reliability of experimental outcomes.
● Early Uniform Growth and Optimal Efficacy Experiment Window
The model achieves uniform growth in its early stages, allowing efficacy experiments to be conducted between P2 and P5 generations. This approach circumvents issues associated with property variations and model waste resulting from multiple passages, while reducing the remaining groups to 20%, without compromising experiment quality, significantly lowering experimental costs.
● Ideal Companion: PBMC Immunocompromised Humanized Model
Pairing the InnovateBio PDX In Vivo Drug Efficacy Model with the PBMC immunocompromised humanized model creates an ideal platform for tumor immunity research. This fusion provides researchers with a more comprehensive and authentic perspective.
● Leading the Era of Innovation
The InnovateBio PDX In Vivo Drug Efficacy Model unites stability and efficacy harmoniously within efficacy evaluation. Our focus extends beyond model stability to optimizing experimental efficiency. Join us now in spearheading an era of innovation in efficacy evaluation. Contact us to explore the boundless potential of this pioneering model that is shaping the landscape of research! #InnovateBioPDXInVivo #EfficacyEvaluationInnovation
Cancer types | Number of models |
Hematologic malignancies (HEMATO) | 3 |
Skin (SK) | 6 |
Musculoskeletal and vascular systems (MSKV) | 17 |
Nervous system (NS) | 1 |
Endocrine System (ES) | 10 |
Urinary system (US) | 3 |
Female reproductory system (FRS) | 40 |
Male reproductory system (MRS) | 0 |
Head and neck (HNC) | 12 |
Torax (TX) | 16 |
Digestive system (DS) | 197 |
Substitute model platform applied in preclinical experiments
- Tel 15010000264
- E-mail limy@imodels.tech
- Tel 13810723384
- Top
InnoModels Biotechnology (Beijing) Co., Ltd.
TEL:15010000264 13810723384
Email:cndw@imodels.tec
Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing
Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company